Inherited gene variant shields blood stem cells from age-related clonal expansion
A common noncoding variant lowers MSI2 in blood stem cells, slowing clonal hematopoiesis and cutting myeloid cancer risk, pointing to new prevention targets.
Resumo
As we age, blood stem cells acquire mutations that can expand into clones, a condition called clonal hematopoiesis (CH) that raises the risk of blood cancers and other chronic diseases. Using a meta-analysis of 43,619 CHIP carriers and 598,761 controls, researchers found a common variant, rs17834140-T, at chromosome 17q22 that is the most protective CHIP variant identified. It weakens a GATA2-bound enhancer and selectively lowers the RNA-binding protein MSI2 in blood stem cells. This reduces stem cell self-renewal and fitness, slows clone growth over time, and blunts the advantage of ASXL1 mutations. Carriers also had lower risk of myeloid malignancies. The findings suggest that inhibiting MSI2 or its targets could be a strategy for blood cancer prevention.
Resumo Detalhado
Clonal hematopoiesis of indeterminate potential (CHIP) is common in older adults. Mutated blood stem cells expand and raise the risk of myeloid malignancies (MyMs), cardiovascular disease and other chronic disorders. Most clones never become large, which suggests some people carry natural protection. Identifying that protection could point to ways of preventing blood cancer.
The team ran a GWAS meta-analysis of 43,619 CHIP carriers and 598,761 controls (All of Us, UK Biobank, Geisinger). The strongest protective signal was a haplotype at 17q22 (odds ratio 0.84 per allele; homozygotes had about 30% lower risk). Protection applied across driver genes: DNMT3A (OR 0.81), TET2 (0.87), ASXL1 (0.74) and JAK2 (0.48). Carriers also had lower risk of MyMs overall (OR 0.80), myeloproliferative neoplasms (0.63) and AML (0.83), and showed lower blood cell counts but no other notable phenotype associations.
Fine-mapping pointed to rs17834140-T, which sits in an enhancer that is accessible specifically in hematopoietic stem cells (HSCs) and contacts the MSI2 promoter. The T allele breaks a GATA-binding site, reduces GATA2 binding and chromatin accessibility, and halves enhancer activity in reporter assays. CRISPR deletions of the site in primary human HSPCs lowered MSI2 mRNA and protein (roughly 20 to 30%). This reduced long-term HSC numbers in culture. In mouse xenografts it reduced engraftment, serial replating and stem cell maintenance, and shifted cells toward myeloid differentiation, partially mimicking full MSI2 knockout.
Using MSI2-HyperTRIBE, the authors mapped MSI2-bound RNAs in human HSPCs and combined them with single-cell RNA-seq to define a 208-gene network of direct targets down-regulated in resilient HSCs. The network includes known regulators (CDK6, SYNCRIP, HSP90AA1) and new candidates (TFRC, DKC1, H3-3B). It was up-regulated in TET2- and ASXL1-mutant cells, and high MSI2 or network expression predicted poorer AML outcomes. In 513 people with persistent CHIP sampled about 6 years apart, T carriers had slower clone growth (median −0.31%/year vs 0.12%/year in non-carriers) and higher odds of the clone becoming undetectable (OR 1.82). Lowering MSI2 in human HSPCs reduced the fitness advantage of ASXL1 mutations. In mice, MSI2 overexpression plus Asxl1 loss produced MDS-like features.
The work suggests that partial, stem cell-specific MSI2 reduction is well tolerated and protective. It may act by shrinking the effective stem cell pool, by blunting the advantage of acquired mutations, or both. Caveats include reliance on in vitro and xenograft models, and the ASXL1 transience signal was borderline (P = 0.057). The cohorts were largely of European ancestry, and no MSI2-targeting preventive therapy has been tested in humans.
Principais Descobertas
- The 17q22 haplotype was the most protective CHIP locus in 43,619 carriers (OR 0.84), with protection across DNMT3A, TET2, ASXL1 and JAK2 clones.
- Carriers had lower risk of myeloid malignancies (OR 0.80), including myeloproliferative neoplasms (OR 0.63) and AML (OR 0.83).
- rs17834140-T disrupts a GATA2 binding site in an HSC-specific enhancer, selectively lowering MSI2 and reducing stem cell self-renewal and engraftment.
- T carriers showed slower CHIP clone growth over ~6 years and higher odds of clones regressing below 2% VAF (OR 1.82).
- Reducing MSI2 blunted the fitness advantage of ASXL1-mutant stem cells, while MSI2 overexpression plus Asxl1 loss caused MDS-like disease in mice.
Metodologia
The authors combined a GWAS meta-analysis (All of Us, UK Biobank, Geisinger), statistical fine-mapping, and functional genomics (ATAC-seq, HiChIP, ChIP, reporter assays). They then used CRISPR editing and CRISPRi in primary human CD34+ HSPCs, NBSGW xenotransplantation, MSI2-HyperTRIBE, single-cell RNA-seq and a mouse Asxl1/MSI2 model. Longitudinal CHIP growth was assessed in 513 individuals with two blood samples about 6 years apart.
Limitações do Estudo
Mechanistic work relied on cultured human cells, xenografts and mouse models, which may not capture decades-long human clonal dynamics. Cohorts were mostly European ancestry, and the ASXL1 clone-transience association was only borderline significant (P = 0.057). Effects of long-term MSI2 inhibition in humans, including on normal hematopoiesis, remain untested.
Gostou deste resumo?
Receba as pesquisas de longevidade mais recentes na sua caixa de entrada toda semana.
Digite seu e-mail para assinar: